top of page

TECHNOLOGY

TECHNOLOGY

TECHNOLOGY

INVESTORS

INVESTORS

TECHNOLOGY

RESOURCES

RESOURCES

RESOURCES

TECHNOLOGY

TECHNOLOGY

TECHNOLOGY

TECHNOLOGY

RESOURCES

Measuring Therapy Effectiveness Through Sensing and Data Control  

 

Find out how we are transforming the medical industry through continuous sensing, computing and transmission to provide the configurable data that physicians need.

 

We've started with intraocular pressure (IOP) sensing to help assess glaucoma therapy effectiveness.

 

 

Media

5a1863973a18271ae9cd636e.png
Injectsense IOP Connect Sensor Platform.jpg

Injectsense Collects $1.7M for its Eye Implant Smaller than A Grain of Rice (Mar. 17, 2022)

mti-masthead_v2.png
glaucoma-physician.png.jpeg
Sensor with coin rice.JPG
Sensor with carrier and dime.jpg

Injectsense Granted $1.7M for IOP Sensor Glaucoma Treatment (Mar. 4, 2022)

An update on Implantable IOP Monitoring, (Mar. 1, 2021)

Screen Shot 2022-05-20 at 10.13.06 PM.png
IMG_8234.JPG

Head in the Clouds: Organ-to-Cloud Technology is Here (March 12, 2020)

Technology

 

Our smart sensor is a self-anchoring platform that interfaces well with media (blood, tissue, other fluids) without interfering with the electronics that support the sensing, computing and transmission of data.

Injectsense Wireless IOP sensor.jpg

Investors

Injectsense received Series B funding in April of 2019, and is currently engaged in fundraising for Series C. 

investors.jpg

Events

 

​

Glaucoma 360

Feb 2-4

San Francisco

 

AGS

March 3-5, 2023

Austin, TX

​

AOS

May 18-20, 2023

Asheville, NC

​

​

The Injectsense Difference

 

Take a look at how the company's Silicon Valley and Twin Cities product teams combine cutting-edge advances in microelectronics with best-in-class medical device development and expertise. 

CAUTION - Investigational Device. Limited by Federal law to investigational use.

.

bottom of page